Want to join the conversation?
Boston, Massachusetts-based $VRTX said that it expects to increase the number of people eligible for Kalydeco and Orkambi drugs in 2016 through label expansion efforts. $VRTX added that it is awaiting for US FDA's approval of cystic fibrosis drug Kalydeco in people with CF ages 2 and older who have certain residual function mutations.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.